GNH USA

Europe — EMA

Infanrix Ipv

GNH USA supplies Infanrix IPV (Diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine), a vaccine for diphtheria, tetanus, pertussis

Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads

Request sourcing

1
Pack/s

What is Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads?

Diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine, the active ingredient in Infanrix IPV, is a vaccine presented as an injectable solution for intramuscular use. It induces immunity against diphtheria, tetanus, pertussis and poliomyelitis in infants and young children.

GNH USA supplies Infanrix IPV as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads used for?

Infanrix IPV is used to immunize against bacterial and viral pathogens that cause serious childhood diseases. - Diphtheria: provides protection by generating antibodies against diphtheria toxin. - Tetanus: induces immunity to tetanus toxin, preventing tetanus infection. - Pertussis (whooping cough): stimulates antibodies to pertussis antigens, reducing disease severity. - Poliomyelitis: creates protective immunity against poliovirus, preventing paralytic polio.

What are the side effects of Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads?

Common side effects are usually mild and transient, reflecting the body’s immune response to the vaccine.

Common Side Effects: - Injection site pain: mild soreness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: temperature rise within 24‑48 hours. - Irritability or fussiness: especially in infants. - Loss of appetite: temporary decrease in feeding.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare neurologic events post‑vaccination. - High fever: temperature >40°C persisting beyond 24 hours. - Prolonged crying: excessive crying lasting more than three hours. - Hypotonic‑hyporesponsive episode: transient loss of muscle tone and responsiveness.

What precautions apply to Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads?

Before administering Infanrix IPV, consider the following safety measures. - Allergy assessment: avoid if known hypersensitivity to any vaccine component. - Immunodeficiency: evaluate patients with compromised immune systems. - Concurrent vaccines: follow recommended immunization schedule and spacing. - Pregnancy and breastfeeding: consult a healthcare professional for risk‑benefit assessment. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads interact with?

Infanrix IPV may interact with other medical products, influencing its effectiveness or safety.

Major Interactions (Avoid): - Live vaccines: avoid simultaneous administration to prevent interference. - Immunoglobulin therapy: may reduce vaccine‑induced immunity. - Blood products: can diminish immune response if given shortly before or after vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever. - Corticosteroids: could blunt the immune response. - Other vaccines: spacing may be required to ensure optimal immunogenicity.

Frequently asked questions

What is Infanrix IPV used for?+
Infanrix IPV is a combination vaccine used to protect infants and young children against four serious diseases: diphtheria, tetanus, pertussis (whooping cough) and poliomyelitis. By stimulating the immune system to produce specific antibodies, it helps prevent infection and the severe complications associated with these bacterial and viral pathogens.
How does the active ingredient in Infanrix IPV work?+
The vaccine contains purified antigens from diphtheria toxin, tetanus toxoid, acellular pertussis components and inactivated poliovirus, adsorbed onto aluminium hydroxide. After intramuscular injection, antigen‑presenting cells process these proteins, activating B‑cells and T‑cells, which then generate protective antibodies that neutralize the toxins and viruses, establishing active immunity.
What is the usual dose of Infanrix IPV?+
The dosing schedule for Infanrix IPV is determined by the prescribing healthcare professional based on national immunization guidelines. Typically, the vaccine is administered as a series of intramuscular injections at specific ages in infancy, but the exact dose and timing should be confirmed by the child's physician.
Is Infanrix IPV safe during pregnancy or breastfeeding?+
Infanrix IPV is generally not recommended for routine use in pregnant women, as safety data are limited. Women who are pregnant should discuss vaccination with their healthcare provider. The vaccine is considered compatible with breastfeeding, but mothers should consult a physician to weigh any potential risks and benefits.
How do I order Infanrix IPV from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, cold‑chain shipping details and required import documentation.
How does Infanrix IPV compare with other combination vaccines?+
Infanrix IPV combines diphtheria, tetanus, acellular pertussis and inactivated poliovirus antigens in a single injection, reducing the number of separate shots required. Compared with older whole‑cell pertussis vaccines, it offers a lower reactogenicity profile while maintaining comparable protection. It is also aligned with EU‑approved immunization schedules.
What are the storage and handling requirements for Infanrix IPV?+
Infanrix IPV must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging to protect from light, and must never be frozen or shaken. Prior to administration, the vaccine should be inspected for particulate matter or discoloration and used promptly after removal from the refrigerator.
How is Infanrix IPV administered?+
The vaccine is given as an intramuscular injection, typically into the anterolateral thigh of infants or the deltoid muscle of older children. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site should be monitored for local reactions following vaccination.
What are the most serious risks associated with Infanrix IPV?+
Serious adverse events are rare but may include anaphylactic reactions, seizures, high fever, prolonged crying episodes, and hypotonic‑hyporesponsive episodes. Any signs of severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or hives, require immediate medical attention.
Who should not receive Infanrix IPV?+
Infanrix IPV should not be administered to individuals with a known severe allergy to any vaccine component, including aluminium salts or the specific antigens. It is also contraindicated in persons with a history of severe anaphylaxis after a previous dose of a DTaP‑IPV vaccine. Consultation with a healthcare provider is essential for those with immunodeficiency or other medical concerns.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads
Route
Intramuscular Use
Manufacturer
Glaxosmithkline Biologicals S.A.
Origin
EU